Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

AT&T

AT&T and Bristol-Myers Squibb are two beaten-down stocks with attractive dividend yields. AT&T has solid operating fundamentals and a low valuation, while Bristol-Myers Squibb has a strong pipeline and is undervalued. Both stocks offer potential for high income and capital appreciation if their valuations reset.

2 Very Cheap Turnarounds Yielding Up To 7%

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine.

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol-Myer Squibb Company (BMY) Q1 2024 Earnings Call Transcript

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)

Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance.

Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

Bristol Myers Squibb beat Wall Street estimates in the first quarter. However, the company slashed its full-year earnings outlook because of recent acquisitions and collaborations.

Why Bristol Myers Squibb Stock Is Sinking Today

Bristol-Myers Squibb (NYSE: BMY ) layoffs are a hot topic on Thursday after the biopharmaceutical company announced major cuts are coming to its workforce. Bristol-Myers Squibb has revealed that it will reduce its headcount by 6%, or roughly 2,200 employees, with these layoffs.

Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts

The stock has been struggling as investors worry about the drugmaker's declining sales and high debt load. The pipeline is promising, however, and management projects $25 billion in new product sales in the future.

Is Bristol Myers Squibb Stock a Millionaire Maker?

Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Merck

Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda helped it post a profit and sales beat. Revenues during the group's first quarter reached US$15.78 billion, topping analysts' expectations of US$15.2 billion.

Merck jumps on profit beat as Bristol Myers Squibb slips to a loss

The pharmaceutical company is implementing an initiative to cut costs by $1.5 billion by 2025 that will include about 2,200 job cuts.

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts

Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.

Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss

AstraZeneca

Sanofi

AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.

AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags

Bristol Myers Squibb Co. on Thursday reported better-than-expected first-quarter results, helped by strong sales of its top-selling blood thinner Eliquis. The drugmaker reported a net loss of $11.911 billion, or $5.89 per share, after net income of $2.262 billion, or $1.07 per share, in the year earlier period.

Bristol Myers Squibb reports narrower-than-expected first-quarter loss, sales top estimates

Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.

Bristol Myers posts quarterly loss, revenue rises 5%

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2024.

Bristol Myers Squibb Reports First Quarter Financial Results for 2024

AbbVie

Amgen

Fidelity MSCI Health Care ETF

iShares U.S. Healthcare ETF

Eli Lilly

Pfizer

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

Gilead Sciences

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know

Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics

BMY has been upgraded to a Buy, with the stock already yielding 5.02% at the time of writing and the Seeking Alpha Quant still grading its dividend safety at B-. Combined with the promising profitability metrics and its overly discounted valuations, it now offers an attractive risk-reward ratio for value and dividend-oriented investors with long-term trajectory. We expect BMY to deliver a mixed FQ1'24 earnings call, attributed to the one-time IPR&D and milestones expenses from the recently closed Karuna, Rayzebio, and Mirati acquisitions.

Is Bristol Myers Squibb A Buy At These Bottom Levels?

Johnson & Johnson

Coca-Cola

Valero Energy

Exxon Mobil

In February, I recommended five one-month momentum plays to buy as Bitcoin ( BTC-USD ) prices surged. The world's largest cryptocurrency is a surprisingly good gauge of bubbly investor sentiment, and our writers at InvestorPlace.com had found several strong candidates to ride the market higher.

5 Crash-Proof Stocks to Buy Immediately

Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients.

Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies

PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $BMY #CART--Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies.

Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster

Verizon

Bristol Myers has an uncertain future, but with a strong track record and impressive cash flow it's still a top healthcare stock to own. Verizon Communications offers investors a mouth-watering yield without much risk.

News for Bristol-Myers Stock (BMY)